Clinical Trial: Rivastigmine Capsules in Patients With Probable Vascular Dementia
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
Brief Summary: The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
Detailed Summary:
Sponsor: Novartis
Current Primary Outcome: Safety and tolerability of rivastigmine for up to 52 weeks of treatment in patients with VaD and probable VaD
Original Primary Outcome:
Current Secondary Outcome: 52 week's treatment with rivastigmine on cognition, activities of daily living, behavior and clinical staging in patients with VaD and probable VaD
Original Secondary Outcome:
Information By: Novartis
Dates:
Date Received: August 11, 2005
Date Started: February 2002
Date Completion:
Last Updated: March 24, 2017
Last Verified: March 2017